Biogen Progresses Tau-Targeting Alzheimer's Candidate to Phase 3 Despite Inconsistent Mid-Stage Efficacy
儘管中期療效不一致，Biogen 仍將針對 Tau 蛋白的阿茲海默症候選藥物推進至第三期臨床試驗
Introduction
Biogen has announced the advancement of its experimental Alzheimer's treatment, diranersen, into late-stage clinical testing following a Phase 2 study with divergent results.
Biogen 宣布，在第二期研究結果分歧後，將其實驗性阿茲海默症治療藥物 diranersen 推進至後期臨床測試。
Main Body
The clinical investigation of diranersen, an antisense oligonucleotide designed to inhibit the production of the tau protein, yielded mixed outcomes. While the study failed to meet its primary efficacy endpoint—specifically the demonstration of a dose-response relationship—Biogen observed a reduction of tau levels in the cerebral and spinal fluid of patients with early-stage Alzheimer's. Notably, these reductions correlated with a deceleration of cognitive decline, with the most pronounced benefits observed at the lowest dosage level.
diranersen 是一種旨在抑制 tau 蛋白產生的反義寡核苷酸，其臨床調查結果不一。雖然研究未能達到主要療效終點（特別是證明劑量反應關係），但 Biogen 觀察到早期阿茲海默症患者的腦脊液中 tau 水平有所下降。值得注意的是，這些下降與認知功能衰退的減緩相關，且在最低劑量水平下觀察到最顯著的益處。
This strategic progression occurs within the context of Biogen's established history of amyloid-targeting therapies, including Leqembi and the previously withdrawn Aduhelm. The transition to tau-targeting represents a methodological shift, as diranersen requires administration via spinal injection. This approach is pursued amidst a competitive landscape where Eli Lilly is similarly investigating tau-reduction mechanisms. Concurrently, the broader pharmaceutical sector is experiencing structural volatility, exemplified by Takeda Pharmaceutical's projected reduction of approximately 4,500 positions by fiscal year 2026 to realize an estimated $1.27 billion in savings by 2028.
這次策略性推進發生在 Biogen 擁有類澱粉蛋白針對性療法（包括 Leqembi 及先前撤回的 Aduhelm）歷史背景之下。轉向針對 tau 蛋白代表了方法論上的轉移，因為 diranersen 需要透過脊髓注射給藥。此方法是在競爭激烈的環境下採取的，Eli Lilly 同樣在研究減少 tau 的機制。與此同時，整個製藥業正經歷結構性動盪，例如武田藥業（Takeda Pharmaceutical）預計到 2026 財年將裁減約 4,500 個職位，以期在 2028 年前實現估計 12.7 億美元的成本節省。
Conclusion
Biogen will proceed with Phase 3 trials for diranersen based on observed cognitive benefits and tau reduction, despite the lack of a traditional dose-response correlation.
儘管缺乏傳統的劑量反應相關性，但基於觀察到的認知益處與 tau 減少，Biogen 將繼續為 diranersen 進行第三期臨床試驗。
Vocabulary Learning
The Art of Nuanced Qualification in High-Stakes Discourse
To bridge the gap from B2 to C2, a student must move beyond simple contrast (e.g., 'but', 'however') and master the Paradox of Concession. In the provided text, the author navigates a precarious logical space: admitting failure while justifying progress.
⧫ The Linguistic Pivot: "Despite" and "Divergent"
Observe the phrasing: "...into late-stage clinical testing following a Phase 2 study with divergent results."
At a B2 level, a writer might say "the results were different" or "the results were bad, but they are continuing." A C2 practitioner uses divergent to imply a sophisticated split in data—suggesting that while one metric failed, another succeeded. This transforms a 'failure' into a 'complex data set.'
⧫ Syntactic Subordination for Strategic Framing
Look at the construction:
*"While the study failed to meet its primary efficacy endpoint... Biogen observed a reduction of tau levels..."
By placing the failure in a dependent clause (the While... clause) and the success in the independent main clause, the writer psychologically minimizes the negative information. The failure becomes a mere condition, while the observation of tau reduction becomes the primary fact of the sentence. This is the hallmark of C2 academic and corporate rhetoric: Information Hierarchy via Syntax.
⧫ Lexical Precision: The "Structural Volatility" Shift
Note the transition from the specific drug trial to the broader industry. The term "structural volatility" is a high-level abstraction. It replaces simpler terms like "economic instability" or "company changes."
C2 Mastery Tip: Whenever you describe a chaotic situation, avoid emotional adjectives (e.g., "terrible", "messy"). Instead, use nominalization (turning a process into a noun phrase) like "structural volatility" to create a sense of objective, scholarly distance.
⧫ The "Notably" Anchor
The word "Notably" functions here not just as a transition, but as a discourse marker of significance. It signals to the reader: "Discard the previous failure; focus on this specific correlation." It is a tool for steering the reader's intellectual attention.